TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Nine US lawmakers, led by Representative Yvette D. Clarke, have asked Revlon CEO Michelle Peluso to respond to FDA findings at the company’s Oxford, North Carolina facility. The FDA’s June warning cited deficiencies in testing incoming talc for asbestos and in quality controls; the agency requested testing, a risk assessment and a remediation plan. The available report does not say whether Revlon has replied or detail the status of corrective work.
Nine members of Congress have written to Revlon Group Holdings CEO Michelle Peluso seeking answers after the Food and Drug Administration cited testing and quality-control deficiencies at the company’s Oxford, North Carolina, manufacturing facility. The intervention brings congressional scrutiny to an FDA warning involving over-the-counter drug manufacturing and the company’s controls for talc and other product standards.
The letter was led by Representative Yvette D. Clarke and follows an FDA warning letter issued in June. According to the source report, the agency said Revlon had not demonstrated adequate testing of incoming talc for asbestos. It also identified deficiencies in product specifications and quality controls, including microbiological standards for yeast and mould.
The FDA requested that Revlon test affected talc or finished products, conduct a risk assessment and provide a remediation plan. Those requests describe steps sought by the agency; the source material does not establish whether the testing or corrective actions have since been completed, or what results they produced.
The lawmakers raised concerns about potential exposure among Black women and girls, pointing to their significant participation in the US beauty and personal care market. That concern is part of the congressional inquiry and should not be read as evidence that consumers were exposed to contaminated products or harmed. The supplied report does not identify specific products, distribution periods or confirmed contamination.
Congress Presses on Consumer Product Controls
The letter adds a congressional dimension to an existing FDA manufacturing matter. For Revlon, lawmakers’ questions may bring further attention to how the company verifies raw materials, tests for contaminants and maintains quality systems at a facility that makes over-the-counter products. The FDA findings described in the source concern whether controls and testing were adequate; they do not, on the information available here, establish that talc or finished products contained asbestos.
For consumers, the central issue is whether the company can demonstrate that potentially affected materials and products were appropriately assessed and that any cited deficiencies are being addressed. The lawmakers’ focus on Black women and girls also highlights the public-health and representation concerns behind the inquiry, while leaving the actual level of risk unresolved. No exposure estimate or health outcome is provided in the source material.
As an affiliate, we earn on qualifying purchases.
The FDA Warning Behind the Letter
The sequence described in the report begins with an FDA warning letter in June concerning Revlon’s Oxford facility. The agency’s concerns involved Current Good Manufacturing Practice requirements for OTC drug manufacturing, including talc testing and quality-control specifications. Such findings concern the systems used to assure product quality; the warning’s cited deficiencies should not be conflated with a finding that a product caused harm.
After the warning, nine lawmakers wrote to Peluso seeking information. The report cites clarke.house as its source for the congressional action and says the lawmakers linked their questions to the market participation of Black women and girls. It does not provide the full text of the letter, the questions in detail, or a response from Revlon or the FDA.
Product Testing And Revlon’s Response
The available reporting does not say whether Revlon has answered the lawmakers, provided the FDA with a remediation plan or completed the requested testing and risk assessment. It also does not identify the products or batches potentially affected, state whether asbestos or other contaminants were detected, or give the results of any testing.
The full congressional letter and the FDA warning letter are not reproduced in the source material. As a result, the precise questions lawmakers posed, the scope of the agency’s findings and any deadlines or enforcement steps cannot be confirmed here. There is also no confirmed information in the report about consumer exposure or related health effects.
Responses And Corrective Steps
The next developments to watch are a response from Revlon CEO Michelle Peluso and any public update from the FDA on the requested testing, risk assessment and remediation. Those details could clarify what materials or products were reviewed, what the results showed and which corrective measures the company has taken.
Until those records or statements are available, the confirmed account remains limited to the FDA’s cited deficiencies and the lawmakers’ request for answers. The source material gives no response deadline, planned hearing or announced enforcement action, so the timing and form of any further action remain unknown.
Key Questions
What are the lawmakers asking Revlon about?
Nine members of Congress wrote to CEO Michelle Peluso seeking answers after FDA findings at Revlon’s Oxford, North Carolina, facility. The report does not provide the full list of questions in their letter.
What did the FDA identify at the facility?
The FDA cited concerns that Revlon had not demonstrated adequate testing of incoming talc for asbestos, along with deficiencies in specifications and quality controls, including microbiological standards for yeast and mould.
Did the FDA say Revlon products contained asbestos?
The supplied report does not say that asbestos was detected in talc or finished products. It describes a finding about inadequate demonstrated testing and says the FDA requested further testing.
Has Revlon completed the actions requested by the FDA?
The available source does not say whether Revlon completed testing, a risk assessment or a remediation plan, or whether the company has responded to the congressional letter.
Why did lawmakers mention Black women and girls?
The lawmakers raised potential exposure concerns and cited Black women and girls’ significant participation in the US beauty and personal care market. The report does not provide evidence of exposure or a confirmed health impact.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
